Results 1–20 of 100 for evusheld in the 'Written Answers'

Written Answers — Department of Health and Social Care: Evusheld (14 Jun 2022)

Maggie Throup: To date, Evusheld has not been made available to National Health Service patients. Evusheld was granted a conditional marketing authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) on 17 March 2022. However, the initial positive trial data on Evusheld was published prior to the emergence of the Omicron variant. The UK Health Security Agency is testing the efficacy...

Written Answers — Department of Health and Social Care: Evusheld (8 Mar 2022)

Lord Kamall: We are aware that the United States Food and Drug Administration (FDA) listed an emergency use authorisation for Evusheld in December 2021, which was revised on 24 February 2022. The FDA has modified their dosing regimen according to its available data and consider that a higher dose of Evusheld may be more likely to prevent infection by the Omicron subvariants BA.1 and BA.1.1 than the...

Written Answers — Department of Health and Social Care: Evusheld (29 Jun 2022)

Lord Kamall: The Antivirals and Therapeutics Taskforce engages with other nations on the use, deployment and evaluation of therapeutics and antivirals. We understand that more than 20 countries have procured Evusheld and a proportion have begun to deploy the treatment. AstraZeneca announced positive trial data from the PROVENT trial, which showed Evusheld’s efficacy against developing symptomatic...

Written Answers — Department of Health and Social Care: Evusheld (24 May 2022)

Maggie Throup: Evusheld was granted a conditional marketing authorisation by the Medicines and Healthcare products Regulatory Agency on 17 March 2022. However, the initial positive trial data on Evusheld was published prior to the emergence of the Omicron variant. The UK Health Security Agency is currently testing the efficacy of Evusheld against the Omicron variant and the Department and National Health...

Written Answers — Department of Health and Social Care: Evusheld (25 May 2022)

Lord Kamall: We understand that the United States of America has increased the suggested dose of Evusheld, in line with in vitro results showing that Evusheld has reduced efficacy against some Omicron subvariants. The Food and Drug Administration’s in vitro data was pseudovirus data, whereas the tests being conducted by the UK Health Security Agency (UKHSA) are based on live virus data. The European...

Written Answers — Department of Health and Social Care: Evusheld (28 Nov 2022)

Lord Markham: The Government has decided not to procure Evusheld at this time for prevention through emergency routes. This is a decision based on independent clinical advice by the multi-agency RAPID C-19 and a United Kingdom national expert policy working group, which considered all available evidence for whether treatments are likely to be effective at preventing symptomatic infection, hospitalisation...

Written Answers — Department of Health and Social Care: Evusheld (4 Jul 2022)

Lord Mendelsohn: To ask Her Majesty's Government, further to the approval of Evusheld by the Medicine and Healthcare products Regulatory Agency on 17 March, when they plan to announce their policy on the provision of Evusheld; and if they are not yet ready to make an announcement, what progress they have made on developing the clinical commissioning policy for Evusheld.

Written Answers — Department of Health and Social Care: Evusheld (30 Jun 2022)

Maggie Throup: Evusheld was granted a conditional marketing authorisation by the Medicines and Healthcare products Regulatory Agency on 17 March 2022. However, the initial positive trial data for Evusheld was published prior to the emergence of the Omicron variant. The UK Health Security Agency has conducted the efficacy of Evusheld against the Omicron variants and initial data for BA.1 and BA.2 has been...

Written Answers — Department of Health and Social Care: Evusheld (8 Nov 2022)

Lord Markham: The National Institute for Health and Care Excellence (NICE) is conducting a Health Technology Evaluation of Evusheld, which will provide guidance on the use of Evusheld in the National Health Service. This evaluation is in development with publication expected in spring 2023. If the NICE recommends its use as a pre-exposure prophylactic is clinically and cost effective, the NHS will make...

Written Answers — Department of Health and Social Care: Members: Correspondence (26 Jan 2023)

Will Quince: On 15 December 2022, we wrote to patient groups and to MPs, to provide an update on COVID-19 treatments this winter. This correspondence did not refer to Evusheld campaigners’ request for a meeting because the purpose of this letter was to provide an update on the Department’s latest position on Evusheld. The Department has met with Evusheld campaigners on multiple occasions and...

Written Answers — Department of Health and Social Care: Evusheld (17 May 2022)

Maggie Throup: Evusheld was granted a conditional marketing authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) on 17 March 2022. However, the initial positive trial data on Evusheld was published prior to the emergence of the Omicron variant. Following its approval, the MHRA had indicated uncertainty on the appropriate dose needed for protection against Omicron. The UK Health...

Written Answers — Department of Health and Social Care: Evusheld (8 Nov 2022)

Lord Markham: The Department has held regular discussions with AstraZeneca on the potential supply, procurement and cost of Evusheld. The Department continues to explore how further data about Evusheld’s effectiveness can be obtained, including encouraging AstraZeneca to continue discussions with the Antivirals and Therapeutics Taskforce on the potential for further research. Clinical advisers have...

Written Answers — Department of Health and Social Care: Evusheld (27 Oct 2022)

Lord Markham: Evusheld received a conditional marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) on 17 March 2022, following trials conducted during the non-Omicron variant wave of the COVID-19 pandemic. The PROVENT study provided data on effectiveness of Evusheld against the alpha, beta, delta and epsilon variants. It was noted that there was a lack of data...

Written Answers — Department of Health and Social Care: Evusheld (3 Nov 2022)

Will Quince: Based on the evidence and after careful analysis and consideration, the UK Government has decided not to procure Evusheld for prevention through emergency routes at this time. However, the UK Government has referred Evusheld to the National Institute for Health and Care Excellence (NICE) for evaluation, which provides evidence-based, rigorous evaluation of the clinical and cost effectiveness...

Written Answers — Department of Health and Social Care: Evusheld (21 Jun 2022)

Maggie Throup: AstraZeneca commissioned the UK Health Security Agency (UKHSA) to undertake testing on the effectiveness of Evusheld against the Omicron variants and initial data for the BA.1 and BA.2 variants has been shared. However, AstraZeneca has not commissioned the UKHSA to initiate testing for the Omicron variant BA.4. After reviewing the data, AstraZeneca can determine whether to commission further...

Written Answers — Department of Health and Social Care: Evusheld (28 Nov 2022)

Lord Markham: The Government has decided not to procure Evusheld for prevention through emergency routes at this time. This is based on independent clinical advice by the multi-agency RAPID C-19 and a United Kingdom national expert policy working group, which concluded that there is insufficient evidence of benefit to recommend deployment. While the Medicines and Healthcare products Regulatory Agency...

Written Answers — Department of Health and Social Care: Evusheld (13 Oct 2022)

Robert Jenrick: The UK Health Security Agency began testing of Evusheld in March 2022, which was completed in May 2022. The decision not to procure Evusheld at this time for prevention through emergency routes is based on independent clinical advice by the multi-agency RAPID C-19 and a national expert policy working group. The decision is based on a range of evidence, including clinical trial data, in vitro...

Written Answers — Department of Health and Social Care: Evusheld (23 Jan 2023)

Lord Markham: The decision not to procure Evusheld for prevention through emergency routes is not based on cost considerations, but rather on independent clinical advice by RAPID C-19 (a multi-agency group) and a UK National Expert Policy Working Group. These groups considered a full range of evidence, including clinical trial data, in vitro analysis and emerging observational studies, as well as the...

Written Answers — Department of Health and Social Care: Evusheld (24 Jan 2023)

Will Quince: ...has asked the National Institute for Health and Care Excellence (NICE) as the independent expert body to develop guidance for the National Health Service on the clinical and cost effectiveness of Evusheld in its licensed indications for the treatment and prevention of COVID-19. NICE will develop guidance in line with its established methods and processes for health technology evaluation...

Written Answers — Department of Health and Social Care: Evusheld (28 Apr 2022)

Daisy Cooper: To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 April 2022 to Question 151279, on Evusheld, when the UKHSA began testing Evusheld’s effectiveness against the covid-19 omicron variant; and whether UKHSA has guidance on how long that testing should take.


1 2 3 4 5 > >>

Create an alert

Advanced search

Find this exact word or phrase

You can also do this from the main search box by putting exact words in quotes: like "cycling" or "hutton report"

By default, we show words related to your search term, like “cycle” and “cycles” in a search for cycling. Putting the word in quotes, like "cycling", will stop this.

Excluding these words

You can also do this from the main search box by putting a minus sign before words you don’t want: like hunting -fox

We also support a bunch of boolean search modifiers, like AND and NEAR, for precise searching.

Date range

to

You can give a start date, an end date, or both to restrict results to a particular date range. A missing end date implies the current date, and a missing start date implies the oldest date we have in the system. Dates can be entered in any format you wish, e.g. 3rd March 2007 or 17/10/1989

Person

Enter a name here to restrict results to contributions only by that person.

Section

Restrict results to a particular parliament or assembly that we cover (e.g. the Scottish Parliament), or a particular type of data within an institution, such as Commons Written Answers.

Column

If you know the actual Hansard column number of the information you are interested in (perhaps you’re looking up a paper reference), you can restrict results to that; you can also use column:123 in the main search box.